Logo image of EVGN

EVOGENE LTD (EVGN) Stock Fundamental Analysis

USA - NASDAQ:EVGN - IL0011050551 - Common Stock

1.15 USD
-0.02 (-1.71%)
Last: 11/19/2025, 12:31:31 PM
Fundamental Rating

1

EVGN gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 533 industry peers in the Biotechnology industry. EVGN may be in some trouble as it scores bad on both profitability and health. EVGN does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

EVGN had negative earnings in the past year.
EVGN had a negative operating cash flow in the past year.
EVGN had negative earnings in each of the past 5 years.
In the past 5 years EVGN always reported negative operating cash flow.
EVGN Yearly Net Income VS EBIT VS OCF VS FCFEVGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

EVGN has a Return On Assets (-42.01%) which is comparable to the rest of the industry.
Industry RankSector Rank
ROA -42.01%
ROE N/A
ROIC N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
EVGN Yearly ROA, ROE, ROICEVGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 200 400 600 800 1K

1.3 Margins

EVGN has a Gross Margin of 47.41%. This is in the better half of the industry: EVGN outperforms 74.86% of its industry peers.
EVGN's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for EVGN so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 47.41%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
EVGN Yearly Profit, Operating, Gross MarginsEVGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -1K -2K -3K

More info and screens

1

2. Health

2.1 Basic Checks

EVGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVGN has more shares outstanding
EVGN has less shares outstanding than it did 5 years ago.
Compared to 1 year ago, EVGN has a worse debt to assets ratio.
EVGN Yearly Shares OutstandingEVGN Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
EVGN Yearly Total Debt VS Total AssetsEVGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

Based on the Altman-Z score of -12.55, we must say that EVGN is in the distress zone and has some risk of bankruptcy.
With a Altman-Z score value of -12.55, EVGN is not doing good in the industry: 76.55% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -12.55
ROIC/WACCN/A
WACC5.06%
EVGN Yearly LT Debt VS Equity VS FCFEVGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M 60M 80M 100M

2.3 Liquidity

A Current Ratio of 1.89 indicates that EVGN should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.89, EVGN is doing worse than 77.86% of the companies in the same industry.
EVGN has a Quick Ratio of 1.76. This is a normal value and indicates that EVGN is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.76, EVGN is doing worse than 78.05% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.89
Quick Ratio 1.76
EVGN Yearly Current Assets VS Current LiabilitesEVGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

EVGN shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 43.18%, which is quite impressive.
The Revenue for EVGN has decreased by -29.79% in the past year. This is quite bad
Measured over the past years, EVGN shows a very strong growth in Revenue. The Revenue has been growing by 62.55% on average per year.
EPS 1Y (TTM)43.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
Revenue 1Y (TTM)-29.79%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-3.28%

3.2 Future

EVGN is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.84% yearly.
EVGN is expected to show a decrease in Revenue. In the coming years, the Revenue will decrease by -9.70% yearly.
EPS Next Y29.49%
EPS Next 2Y28.03%
EPS Next 3Y19.84%
EPS Next 5YN/A
Revenue Next Year-56.03%
Revenue Next 2Y-29.71%
Revenue Next 3Y-9.7%
Revenue Next 5YN/A

3.3 Evolution

The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
EVGN Yearly Revenue VS EstimatesEVGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 20M 40M 60M 80M
EVGN Yearly EPS VS EstimatesEVGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2020 2021 2022 2023 2024 2025 2026 2027 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

EVGN reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EVGN. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EVGN Price Earnings VS Forward Price EarningsEVGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80 100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EVGN Per share dataEVGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -1 -2

4.3 Compensation for Growth

EVGN's earnings are expected to grow with 19.84% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.03%
EPS Next 3Y19.84%

More info and screens

0

5. Dividend

5.1 Amount

EVGN does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

EVOGENE LTD

NASDAQ:EVGN (11/19/2025, 12:31:31 PM)

1.15

-0.02 (-1.71%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-19 2025-08-19/bmo
Earnings (Next)11-20 2025-11-20/bmo
Inst Owners1.66%
Inst Owner Change17.94%
Ins Owners0.96%
Ins Owner ChangeN/A
Market Cap10.03M
Revenue(TTM)6.63M
Net Income(TTM)-14.25M
Analysts82.86
Price Target2.55 (121.74%)
Short Float %0.75%
Short Ratio0.72
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)10.82%
Min EPS beat(2)3.52%
Max EPS beat(2)18.12%
EPS beat(4)3
Avg EPS beat(4)25.65%
Min EPS beat(4)-27.16%
Max EPS beat(4)108.11%
EPS beat(8)7
Avg EPS beat(8)24.47%
EPS beat(12)11
Avg EPS beat(12)24.66%
EPS beat(16)12
Avg EPS beat(16)17.11%
Revenue beat(2)0
Avg Revenue beat(2)-14.98%
Min Revenue beat(2)-23.14%
Max Revenue beat(2)-6.81%
Revenue beat(4)0
Avg Revenue beat(4)-31.15%
Min Revenue beat(4)-56.44%
Max Revenue beat(4)-6.81%
Revenue beat(8)4
Avg Revenue beat(8)16.37%
Revenue beat(12)6
Avg Revenue beat(12)40.72%
Revenue beat(16)8
Avg Revenue beat(16)42.34%
PT rev (1m)0%
PT rev (3m)-28.57%
EPS NQ rev (1m)0%
EPS NQ rev (3m)34.4%
EPS NY rev (1m)-0.7%
EPS NY rev (3m)2.71%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-28.18%
Revenue NY rev (1m)0%
Revenue NY rev (3m)-28.37%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.51
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-1.12
Fwd EYN/A
FCF(TTM)-2.09
FCFYN/A
OCF(TTM)-2.02
OCFYN/A
SpS0.76
BVpS-0.41
TBVpS-0.41
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -42.01%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 47.41%
FCFM N/A
ROA(3y)-45.19%
ROA(5y)-40.9%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5Y-18.86%
F-Score2
Asset Turnover0.2
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 31.7%
Cap/Sales 8.7%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.89
Quick Ratio 1.76
Altman-Z -12.55
F-Score2
WACC5.06%
ROIC/WACCN/A
Cap/Depr(3y)33.47%
Cap/Depr(5y)32.69%
Cap/Sales(3y)30.31%
Cap/Sales(5y)49.54%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)43.18%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%41.51%
EPS Next Y29.49%
EPS Next 2Y28.03%
EPS Next 3Y19.84%
EPS Next 5YN/A
Revenue 1Y (TTM)-29.79%
Revenue growth 3Y109.17%
Revenue growth 5Y62.55%
Sales Q2Q%-3.28%
Revenue Next Year-56.03%
Revenue Next 2Y-29.71%
Revenue Next 3Y-9.7%
Revenue Next 5YN/A
EBIT growth 1Y14.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year51.44%
EBIT Next 3Y20.31%
EBIT Next 5YN/A
FCF growth 1Y15.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y14.68%
OCF growth 3YN/A
OCF growth 5YN/A

EVOGENE LTD / EVGN FAQ

Can you provide the ChartMill fundamental rating for EVOGENE LTD?

ChartMill assigns a fundamental rating of 1 / 10 to EVGN.


What is the valuation status for EVGN stock?

ChartMill assigns a valuation rating of 0 / 10 to EVOGENE LTD (EVGN). This can be considered as Overvalued.


How profitable is EVOGENE LTD (EVGN) stock?

EVOGENE LTD (EVGN) has a profitability rating of 1 / 10.


Can you provide the expected EPS growth for EVGN stock?

The Earnings per Share (EPS) of EVOGENE LTD (EVGN) is expected to grow by 29.49% in the next year.